MELATONIN TARGET PROTEINS: INTERACTIONS AND FUNCTIONS
- Authors: Glebezdina N.S.1
-
Affiliations:
- Institute of Ecology and Genetics of Microorganisms of the Ural Branch RAS, Perm, Russia
- Section: Immunological readings in Chelyabinsk
- Submitted: 30.03.2025
- Accepted: 25.05.2025
- URL: https://rusimmun.ru/jour/article/view/17210
- DOI: https://doi.org/10.46235/1028-7221-17210-MTP
- ID: 17210
Cite item
Full Text
Abstract
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is the primary hormone of the pineal gland, however its synthesis also occurs in various extrapineal tissues, including the brain, retina, retinal pigment epithelium, gastrointestinal tract, bone marrow, thymus, lymphocytes, and skin. Melatonin is an amphiphilic indole derivative that combines hydrophilic (methyl and amide groups) and hydrophobic (indole core) molecular domains. Due to its unique structure, which ensures high bioavailability, and the presence of the hormone and enzymatic mechanisms for its synthesis in various organs and tissues, melatonin is involved in regulating numerous physiological processes, highlighting its significant role in maintaining systemic homeostasis. The pleiotropic effects of melatonin are due to a combination of its direct molecular interactions and mediated regulatory mechanisms. On the one hand, melatonin exhibits the properties of a powerful endogenous antioxidant capable of directly neutralizing reactive oxygen and nitrogen species. On the other hand, its physiological effects are realized through binding to specific protein targets, as well as through secondary mechanisms, including the activation of antioxidant defense, metabolic, and epigenetic modulation. Of particular interest is the interaction of the hormone with numerous extracellular and intracellular molecular targets, with binding affinity varying across a wide range of concentrations. Research over recent decades has identified approximately twenty distinct protein targets of melatonin, spanning a broad spectrum of functional categories - from well-characterized receptors (membrane-bound and nuclear) to non-canonical targets. These include: enzymes (quinone reductase 2, matrix metalloproteinase-9, protein phosphatase 2A, pepsin), ion channels, transport and structural proteins (glucose transporter GLUT1, oligopeptide transporters PEPT1 and PEPT2, serum albumin, tubulin), calcium-binding proteins (calmodulin, protein kinase C, calreticulin). The search for melatonin targets continues. It is hypothesized that, in addition to its mediated effects, the hormone may directly modulate the activity of the membrane resistance protein P-glycoprotein and NAD⁺-dependent deacetylases – sirtuins SIRT1 and SIRT3.
Conclusions. Studying melatonin targets is crucial for analyzing its pharmacodynamic effects, while the search for new targets opens perspectives for understanding the hormone’s non-circadian functions, such as neuroprotection, anticancer effects, and metabolic modulation.
Keywords
About the authors
Natalia Sergeevna Glebezdina
Institute of Ecology and Genetics of Microorganisms of the Ural Branch RAS, Perm, Russia
Author for correspondence.
Email: glebezdina_n@mail.ru
ORCID iD: 0000-0002-9891-0509
Candidate of Biology, Researcher of Laboratory of Immunoregulation
Russian Federation, 13, Golev str., Perm, 614081, RussiaReferences
- Andrabi S.A., Sayeed I., Siemen D., Wolf G., Horn T.F. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J., 2004, Vol. 18, no. 7, pp. 869–871. doi: 10.1096/fj.03-1031fje
- Arribas R.L., Romero A., Egea J., de Los Rios C. Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. Br. J. Pharmacol., 2018, Vol. 175, no. 16, pp. 3220–3229. doi: 10.1111/bph.14365.
- Benitez-King G., Argueta J., Miranda-Riestra A., Munoz-Delgado J., Estrada-Reyes R. Interaction of the Melatonin/Ca2+-CaM Complex with Calmodulin Kinase II: Physiological Importance. Mol. Pharmacol., 2024, Vol. 106, no. 1, pp. 3–12. doi: 10.1124/molpharm.123.000812.
- Benitez-King G., Hernandez M.E., Tovar R., Ramirez G. Melatonin activates PKC-alpha but not PKC-epsilon in N1E-115 cells. Neurochem. Int., 2001, Vol. 39, no. 2, pp. 95–102. doi: 10.1016/s0197-0186(01)00021-3.
- Boutin J.A., Ferry G. Is There Sufficient Evidence that the Melatonin Binding Site MT3 Is Quinone Reductase 2? J. Pharmacol. Exp. Ther., 2019, Vol. 368, no. 1, pp. 59–65. doi: 10.1124/jpet.118.253260.
- Chen Y., Wu X., Yang X., Liu X., Zeng Y., Li J. Melatonin antagonizes ozone-exacerbated asthma by inhibiting the TRPV1 channel and stabilizing the Nrf2 pathway. Environ. Sci. Pollut. Res. Int., 2021, Vol. 28, no. 42, pp. 59858–59867. doi: 10.1007/s11356-021-14945-9.
- Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International union of basic and clinical pharmacology. LXXV. nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev., 2010, Vol. 62, no. 3, pp. 343–380. doi: 10.1124/pr.110.002832.
- Hevia D., Gonzalez-Menendez P., Quiros-Gonzalez I., Miar A., Rodriguez-Garcia A., Tan D.X., Reiter R.J., Mayo J.C., Sainz R.M. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J. Pineal. Res., 2015, Vol. 58, no. 2, pp. 234–50. doi: 10.1111/jpi.12210.
- Huo X., Wang C., Yu Z., Peng Y., Wang S., Feng S., Zhang S., Tian X., Sun C., Liu K., Deng S., Ma X. Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential. J. Pineal. Res., 2017, Vol. 62, no. 4, pp. e12390. doi: 10.1111/jpi.12390.
- Li X., Wang S. Binding of glutathione and melatonin to human serum albumin: a comparative study. Colloids Surf B Biointerfaces, 2015, Vol. 125, pp. 96–103. doi: 10.1016/j.colsurfb.2014.11.023.
- Li X., Ni T. Binding of glutathione and melatonin to pepsin occurs via different binding mechanisms. Eur. Biophys., 2016, Vol. J 45, pp. 165–174. doi: 1007/s00249-015-1085-y.
- Liu L., Labani N., Cecon E., Jockers, R. Melatonin Target Proteins: Too Many or Not Enough? Front Endocrinol (Lausanne), 2019, Vol. 10, pp. 791. doi: 10.3389/fendo.2019.00791.
- Macias M., Escames G., Leon J., Coto A., Sbihi Y., Osuna A., Acuna-Castroviejo D. Calreticulin-melatonin. An unexpected relationship. Eur. J. Biochem., 2003, Vol. 270, no. 5, pp. 832–840. doi: 10.1046/j.1432-1033.2003.03430.x.
- Rudra D.S., Pal U., Maiti N.C., Reiter R.J., Swarnakar S. Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J. Pineal. Res., 2013, Vol. 54, no. 4, pp. 398-405. doi: 10.1111/jpi.12034.
- Slominski R.M., Reiter R.J., Schlabritz-Loutsevitch N., Ostrom R.S., Slominski A.T. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol. Cell. Endocrinol., 2012, Vol. 351, no. 2, pp. 152–166. https://doi.org/10.1016/j.mce.2012.01.004.
Supplementary files
